Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for relapse prevention after opioid detoxification
2014-002708-26Phase 2Terminated
- Sponsor
- University of Surrey
- Start
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) and substance use disorder (SUD) comparing Syntocinon with Placebo (2 arms). Primary endpoint: Retention rates in rehabilitation programme. Started Nov 2014; status: terminated.
02
Drugs
oxytocin
03
Conditions
opioid use disorder (OUD)substance use disorder (SUD)
Beyond the preview
Go deeper on 2014-002708-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002708-26.